Natural history of AD |
|
|
Death during the mild stage |
0.038 (0.024) |
Morris et al.2323.MorrisJC,HeymanA,MohsRC,HughesJP,van BelleG,FillenbaumG, et al. The consortium to establish a registry for Alzheimer's disease (CERAD). Part I. Clinical and neuropsychological assessment of Alzheimer's disease.Neurology.1989;39:1159-65. and Spackman et al.1818.SpackmanDE,KadiyalaS,NeumannPJ,VeenstraDL,SullivanDS. Measuring Alzheimer disease progression with transition probabilities: estimates from NACC-UDS.Curr Alzheimer Res.2012;9:1050-8.
|
Death during the moderate stage |
0.134 (0.081) |
|
Stable-mild stage |
0.694 (0.113) |
|
Moderate-mild stage |
0.057 (0.014) |
|
Severe-mild stage |
0.001 (0.001) |
|
Death during the severe stage |
0.317 (0.164) |
|
Mild-moderate stage |
0.240 (0.116) |
|
Mild-severe stage |
0.028 (0.021) |
|
Stable-moderate stage |
0.533 (0.032) |
|
Moderate-severe stage |
0.227 (0.062) |
|
Severe-moderate stage |
0.014 (0.014) |
|
Stable-severe stage |
0.670 (0.178) |
|
Rivastigmine |
|
|
Mild stage |
0.724 (0.110) |
Fenn & Gray2020.FennP,GrayA. Estimating long-term cost savings from treatment of Alzheimer's disease. A modelling approach.Pharmacoeconomics.1999;16:165-74. and Hauber et al.1919.HauberAB,GnanasakthyA,MauskopfJA. Savings in the cost of caring for patients with Alzheimer's disease in Canada: an analysis of treatment with rivastigmine.Clin Ther.2000;22:439-51.
|
Moderate stage |
0.274 (0.231) |
|
Severe stage |
0.070 (0.071) |
|
Death during the mild stage |
0.038 (0.024) |
|
Death during the moderate stage |
0.134 (0.115) |
|
Death during the severe stage |
0.316 (0.241) |
|
Donepezil |
|
|
Stable-mild stage |
0.668 (0.092) |
Stewart et al.,2424.StewartA,PhillipsR,DempseyG. Pharmacotherapy for people with Alzheimer's disease: a Markov-cycle evaluation of five years' therapy using donepezil.Int J Geriatr Psychiatry.1998;13:445-53. Neumann et al.,2222.NeumannPJ,HermannRC,KuntzKM,ArakiSS,DuffSB,LeonJ, et al. Cost-effectiveness of donepezil in the treatment of mild or moderate Alzheimer's disease.Neurology.1999;52:1138-45. Jonsson et al.,2121.JonssonL,LindgrenP,WimoA,JonssonB,WinbladB. The cost-effectiveness of donepezil therapy in Swedish patients with Alzheimer's disease: a Markov model.Clin Ther.1999;21:1230-40. and Ikeda et al.1717.IkedaS,YamadaY,IkegamiN. Economic evaluation of donepezil treatment for Alzheimer’s disease in Japan.Dement Geriatr Cogn Disord.2002;13:33-9.
|
Mild-moderate stage |
0.210 (0.097) |
|
Mild-severe stage |
0.018 (0.022) |
|
Death during the mild stage |
0.038 (0.024) |
|
Stable-moderate stage |
0.560 (0.057) |
|
Moderate-severe stage |
0.261 (0.068) |
|
Death during the moderate stage |
0.134 (0.115) |
|
Moderate-mild stage |
0.089 (0.058) |
|
Severe-mild stage |
0.001 (0.001) |
|
Severe-moderate stage |
0.014 (0.014) |
|
Stable-severe stage |
0.835 (0.208) |
|
Death during severe stage |
0.085 (0.231) |
|
Utility44.NitriniR,BottinoCM,AlbalaC,Custodio CapuñayNS,KetznoianC,Libre RodriguezJJ, et al. Prevalence of dementia in Latin America: a collaborative study of population-based cohorts.Int Psychogeriatr.2009;21:622-30.
|
|
|
Mild AD with NH |
0.695 (0.021) |
Ikeda et al.,1717.IkedaS,YamadaY,IkegamiN. Economic evaluation of donepezil treatment for Alzheimer’s disease in Japan.Dement Geriatr Cogn Disord.2002;13:33-9. Hartz et al.,3939.HartzS,GetsiosD,TaoS,BlumeS,MaclaineG. Evaluating the cost effectiveness of donepezil in the treatment of Alzheimer’s disease in Germany using discrete event simulation.BMC Neurol.2012;12:2. Jonsson et al.,3737.JonssonL,AndreasenN,KilanderL,SoininenH,WaldemarG,NygaardH, et al. Patient- and proxy-reported utility in Alzheimer disease using the EuroQoL.Alzheimer Dis Assoc Disord.2006;20:49-55. Naglie et al.,3838.NaglieG,TomlinsonG,TanseyC,IrvineJ,RitvoP,BlackSE, et al. Utility-based quality of life measures in Alzheimer’s disease.Qual Life Res.2006;15:631-43. Mesterton et al.,3636.MestertonJ,WimoA,ByA,LangworthS,WinbladB,JonssonL. Cross sectional observational study on the societal costs of Alzheimer’s disease.Curr Alzheimer Res.2010;7:358-67. and Oremus et al.3535.OremusM,TarrideJE,ClaytonN, Raina P; Canadian Willingness-to-Pay Study Group, Raina P. Health utility scores in Alzheimer’s disease: differences based on calculation with American and Canadian preference weights.Value Health.2014:17:77-83.
|
Moderate AD with NH |
0.510 (0.042) |
|
Severe AD with NH |
0.340 (0.042) |
|
Mild AD with AChEI |
0.774 (0.104) |
|
Moderate AD with AChEI |
0.510 (0.042) |
|
Severe AD with AChEI |
0.457 (0.201) |
|